AbbVie

Abbott
Accuray
Allergan
Alzheimer’s
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cardinal Health
Cardiology
Danaher
Dermatology
Diabetes
DSM-5
Editorial
Edwards Lifesciences
Elekta
Eli Lilly
Endo Health Solutions
Forest Laboratories
Gilead
GlaxoSmithKline
Health Care
Hematology
Hepatitis
HIV/AIDS
Hospital
Intercept
Interviews
Intuitive Surgical
Layman's Terms
McLaren Health Care
Medical
Merck
Mylan
Novartis
Nursing
Oncology
Pfizer
Pharmaceuticals
Physician Commentary
Press Releases
Psych Drugs
Psychiatry
Regeneron
Roche
Sangamo
Sanofi
Surgical
Technology
Valeant Pharmaceuticals
Varian

April 20, 2017

Can Hepatitis C Be Eliminated by 2030? On the Path to Zero

AbbVie’s broad commitment to a global effort to cure hepatitis C (HCV) led to a policy, advocacy and awareness initiative called Path to Zero: Fresh Thinking on the Road to Eliminating HCV. April 20, 2017 – The Economist Group’s Path to Zero program, sponsored by AbbVie, aims to foster a global dialogue around innovative solutions […]